Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 5/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492084 | 0.79 | POLB (0.48) | NLRP3AKR1B1 | |
| SCHEMBL25357321 | 0.79 | NLRP3 (0.53) | NLRP3AKR1B1LMNANTRK1RORC | |
| SCHEMBL29492112 | 0.79 | NLRP3 (0.53) | NLRP3AKR1B1LMNANTRK1RORC | |
| SCHEMBL29492205 | 0.75 | NLRP3 (0.43) | NLRP3AKR1B1KMT2A | |
| SCHEMBL26909947 | 0.73 | NLRP3 (0.47) | NLRP3 | |
| SCHEMBL25357791 | 0.73 | NLRP3 (0.53) | NLRP3AKR1B1KMT2ANTRK1 | |
| SCHEMBL24077358 | 0.73 | NLRP3 (0.65) | NLRP3AKR1B1LMNAKMT2A | |
| SCHEMBL25357509 | 0.70 | NLRP3 (0.38) | NLRP3PDE2AAKR1B1 | |
| SCHEMBL25357485 | 0.68 | NLRP3 (1.00) | NLRP3LMNAKMT2A | |
| SCHEMBL26980324 | 0.65 | RBP4 (0.44) | PDE2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4217346-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063876-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| EP-3974415-A1 | NLRP3 MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | NLRP3 1/4885AKT1 3741/4885PDE2A 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.